HALO

Halozyme Therapeutics, Inc. (HALO)

Last Price$61.4(0.0%)
Market Cap$7,773.1M

HALO Rating

HALO Intrinsic Value

Key Highlights:
As of Mar 11, 2025 HALO Relative Value is $44.5, which is overvalued by 27.6%, compared to current share price of $61.4.
As of Mar 11, 2025 HALO DCF Value is $66.4, which is undervalued by 8.1%, compared to current share price of $61.4.
Methodology
Price per share, $
Current share price
61.4

HALO Share Price History

1W 5.7%
1M 7.2%
6M 3.4%
YTD 64.3%
1Y 49.1%
3Y 76.9%
5Y 237.2%
10Y 298.6%
Share Price
Intrinsic Value
Drawdown
Total Return
vs SP500
vs NASDAQ
Crunching data... Almost there!

HALO Stock Metrics

Key stats
Income statement
Balance sheet
Cash Flow Statement
Valuation
Ratios
Per share
Per employee
Dividends & Yields
Base
$7,773.1M
$1,015.3M
Shares Outstanding
127M
Employees
350
Valuation (LTM)
Return on Capital
108.8%
21.2%
33.1%
22.3%
Earnings

HALO Stock Financials

HALO Income Statement Metrics

Annual
Quarterly
LTM

Revenue

$1,015.3M +22.4% YoY

Operating Income

$551.5M +63.4% YoY

Net Income

$444.1M +57.7% YoY

HALO Cash Flow Statement Metrics

Annual
Quarterly
LTM

Operating Cash Flow (OCF)

$479.1M +23.3% YoY

Capital Expenditure (CAPEX)

($10.7M) -30.1% YoY

Free Cash Flow (FCF)

$468.4M +25.5% YoY

HALO Income Statement Overview

Annual
Quarterly
LTM
Dec'15
Dec'16
Dec'17
Dec'18
Dec'19
Dec'20
Dec'21
Dec'22
Dec'23
Dec'24
$1,015.3M 22.4% YoY
$855.9M 34.4% YoY
84.3% margin
Cost of revenue
$159.4M (17.1%) YoY
Operating income
$551.5M 63.4% YoY
54.3% margin
Other: $23.8M
Net interest: $18.1M
Operating expenses
$304.4M 1.7% YoY
Pre-tax income
$557.1M 59.9% YoY
54.9% margin
Net income
$444.1M 57.7% YoY
43.7% margin
Income tax
$113.0M
20.3% tax rate
R&D
$79.0M 3.5% YoY
7.8% of revenue
SG&A
$154.3M 3.5% YoY
15.2% of revenue

HALO Balance Sheet Overview

Annual
Quarterly
LTM
Dec'15
Dec'16
Dec'17
Dec'18
Dec'19
Dec'20
Dec'21
Dec'22
Dec'23
Dec'24
Assets
Liabilities
Total assets
$2,063.5M
Current assets ($1,085.3M, 52.6% of total)
$596.1M (28.9%)
$308.5M (14.9%)
Other current assets
$180.8M (8.8%)
Non-current assets ($978.1M, 47.4% of total)
$401.8M (19.5%)
Other non-current assets
$501.3M (24.3%)
Financial position
$909.7M
$596.1M$1,505.8M
Cash & Short-term Investments
Total Debt

HALO Stock Ratios

HALO Earnings Surprises

Crunching data... Almost there!

HALO Dividends

HALO Dividend Yield

Crunching data... Almost there!

HALO Dividend Per Share

Competing with HALO

Overview
Ratings
Intrinsic Value
Valuation
Growth
Profitability
Health
Capital allocation
Momentum
Earnings
Dividends
Company name
Market Cap
Quality rating
Intrinsic value
1Y Return
Revenue
Free Cash Flow
Revenue growth
FCF margin
Gross margin
ROIC
Total Debt to Equity
$7,773.1M
7.6
$55.1
10.3% overvalued
49.1%
$1,015.3M
$468.4M
22.4%
46.1%
80.8%
33.1%
413.9%
$124.8B
5.7
$187.5
61.6% overvalued
17.8%
$11.0B
($790.3M)
11.5%
(7.2%)
86.1%
(15.0%)
10.7%
$77.0B
6.3
$1,048.3
46.0% undervalued
(25.4%)
$14.2B
$3,597.2M
8.3%
25.3%
84.5%
25.7%
5.7%
$34.4B
5.8
$123.0
78.8% overvalued
50.8%
$2,258.9M
($211.2M)
127.3%
(9.4%)
86.8%
(41.3%)
N/A
$30.7B
5.2
$91.8
61.6% overvalued
60.1%
$2,248.2M
($42.6M)
23.0%
(1.9%)
85.6%
(7.2%)
1,931.9%
$24.0B
5.9
$191.1
94.2% undervalued
2.2%
€2,751.1M
(€229.8M)
(28.0%)
(8.4%)
80.3%
(37.8%)
1.3%
$14.5B
5.4
$71.6
120.5% undervalued
11.2%
$2,263.9M
$2,769.0M
(3.8%)
122.3%
73.9%
14.5%
73.6%
$13.8B
7.7
$542.2
78.1% undervalued
22.0%
$2,877.4M
$1,080.6M
23.6%
37.6%
89.2%
65.4%
4.7%
$13.4B
6.7
$46.9
33.5% overvalued
(18.0%)
$2,850.5M
$475.4M
17.8%
16.7%
78.6%
11.0%
10.7%
$13.3B
5.9
$0.6
96.9% overvalued
330.2%
$0.0
($142.1M)
N/A
N/A
N/A
(3,335.4%)
1.9%
$1,846.9M
5.5
$2,745.6
1,111.0% undervalued
39.9%
$3,316.8M
($1,041.0M)
50.5%
(31.4%)
83.7%
(43.2%)
32.1%

FAQ

What is Halozyme Therapeutics, Inc. (HALO) stock rating?

As of today, Halozyme Therapeutics, Inc. has a stock rating of 8 (out of 10), which is considered Great.

is Halozyme Therapeutics, Inc. (HALO) a good stock to buy?

As of today, Halozyme Therapeutics, Inc. has a Great stock rating, which is 10.3% overvalued. According to Value Sense backtesting, stocks with similar profile tend to outperform the market by 0.5%.